Peregrine Pharmaceuticals Extends Its Agreement for the Development of Tumor Necrosis Therapy -TNT- in the People`s Republic of China
(Business Wire)...The application for regulatory approval was based upon clinical trials conducted at multiple centers in China for the past five years involving patients with various types of cancer such as lung, colorectal, brain, gastric, liver and sarcoma.......Collateral targeting agents are designed to bind to elements of tumors that are common to all solid tumors or are the product of tumor growth....- May 23 11:02 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010523/0253.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines